

7章 SMAの合併症 (齊藤利雄)

47

- 7-1 呼吸不全 47
 - SMA 患者さんの呼吸障害の病態 48
 - 呼吸の評価とモニタ 48
 - 呼吸機能評価とリハビリテーション 50
 - 咳介助・排痰処置 50
 - 人工呼吸療法 51

- 7-2 栄養管理の問題 52
 - 食事摂取障害・嚥下障害 52
 - 摂食様態の特徴 52
 - 食事摂取障害・嚥下障害の心理的課題 53
 - 食事摂取障害・嚥下障害の評価 53
 - 食事摂取障害・嚥下障害のマネジメント 54
 - 胃瘻 55
 - 消化管機能障害 55
 - 消化管機能障害の評価 56
 - 胃食道逆流のマネジメント 56
 - 発育障害, 低栄養・過剰栄養の問題 56

- 7-3 整形外科的問題 57
 - 評価・検査 57
 - 対策 57
 - 脊柱変形の問題 58

8章 SMAの呼吸ケア (石川悠加・三浦利彦・竹内伸太郎)

61

- SMA の呼吸の特徴 61
- 慢性の呼吸ケア・マネジメント 62
- 非侵襲的陽圧換気療法 65
- NPPV の機器 66
- NPPV の導入 68
- 急性呼吸ケア・マネジメント 69
- 挿管への移行 69
- SMA I 型の非侵襲的呼吸ケア 70
- 気管切開人工呼吸 70

9章 リハビリテーション

72

- 9-1 運動機能の評価法 (Hammersmith 運動機能評価スケール) (荒川玲子) 72
- Hammersmith 運動機能評価スケールについて 72
 - 運動機能評価を行うということ 74
- 9-2 リハビリテーションの立場からみた SMA (猪飼哲夫) 74
- 病型と症状 74
 - 筋力低下 75
 - 関節拘縮・変形 75
 - 脊柱側弯変形 75
 - 呼吸・摂食障害 76
 - 認知・知的機能は正常 76
 - 立位・歩行障害 76
- 9-3 SMA のリハビリテーション (機能訓練) (安達みちる) 77
- 機能訓練のポイント 77
 - 筋力低下・関節拘縮に対して 78
 - 側弯に対して 81
 - 無気肺・呼吸への対応 82
- 9-4 日常生活動作と補装具
- 車椅子・装具・コミュニケーション機器など— (長谷川三希子) 85
 - SMA の日常生活動作 (ADL: activities of daily living) について 85
 - 車椅子と坐位保持装置 85
 - 装具について 89
 - パソコン・コミュニケーション機器 90

10章 手術療法

93

- 10-1 食べられない, 飲みこめない—胃瘻 (世川 修) 93
- 胃瘻造設の適応 93
 - 胃瘻造設前の検査 94
 - 胃瘻造設の実際 94
 - 胃瘻造設後の問題点 96

- 10-2 胃食道逆流—噴門形成術 (世川 修) 98
- 噴門形成術の適応 98
 - 噴門形成術の実際 99
 - 噴門形成術後の諸問題 102
- 10-3 側弯—脊柱変形矯正手術
(高相晶士・齋藤 亘・上野正喜・中澤俊之・井村貴之) 102
- 脊柱変形の治療方法 103
 - 手術方法 103
 - 筆者らの経験 104
 - 筆者らの経験の結果 105
 - 考察と今後の展望 105
- 10-4 気管切開および気管喉頭分離術 (松尾真理) 107
- 手術方法 107
 - 合併症 109
 - 日常管理 109

11章 生活・福祉支援, QOLの向上 (富川由美子) 111

- 公費負担制度 111
- 社会保障・福祉制度 112
- 在宅サポート 112

12章 SMAの新しい治療法の開発研究 114

- 12-1 薬物治療の研究の進歩 (西尾久英) 114
- 薬物治療の位置づけ 114
 - 薬物による運動ニューロン治療の二大戦略 114
 - SMN2 遺伝子のスプライシング異常 115
 - 運動ニューロン内の SMN タンパク質の発現増加を目指す治療戦略 115
 - ヒストン脱アセチル化酵素阻害剤 116
 - バルプロ酸の臨床応用 117
 - 運動ニューロン保護を目指す治療戦略 117
 - 治験体制構築の必要性 117

- 12-2 ロボットスーツ HAL の開発研究の進歩 (中島 孝) 119
- ロボットスーツ HAL とは何か 119
 - HAL の構造と動作メカニズム 119
 - HAL を SMA 治療に使う 121
 - 技術的な研究と将来 121
 - 有効性と安全性評価—HAL の治験 122
 - 倫理哲学的な考察 123
- 12-3 ウイルスベクターを用いた治療研究の展開—SMA に対する
遺伝子治療の可能性とその展望 (野本明男・荒川正行) 125
- SMA における遺伝子治療研究の現状 125
 - ウイルスベクター 126
 - 将来への展望 128
- 12-4 再生医療の進歩—iPS 細胞の可能性 (荒川正行) 129
- SMA-iPS 細胞の確立と再生医療研究の進歩 129
 - SMA 再生医療に向けて 129
 - 将来への展望 130

13 章 SMA (脊髄性筋萎縮症) 家族の会とともに 131

- 母親から I 型 131
- 父親から II 型 132
- 本人 III 型 133
- 本人 IV 型 133
- SMA 家族の会からのメッセージ 134

14 章 SMA の専門医療機関・ホームページ (伊藤万由里・梅野愛子) 136

- SMA の専門医療機関・施設リスト 136
- SMA に関するホームページ 143

索引..... 145

Database of Wards for Patients with Muscular Dystrophy in Japan

Toshio Saito¹ and Katsunori Tatara²

¹*Division of Neurology, National Hospital Organization Toneyama National Hospital,*

²*Division of Pediatrics, National Hospital Organization Tokushima National Hospital,
Japan*

1. Introduction

Twenty-seven hospitals in Japan specialize in treatment of muscular dystrophy patients, including inpatient care, of which 26 belong to the National Hospital Organization, and the other is the National Center of Neurology and Psychiatry. Since 1999, Japanese muscular dystrophy research groups investigating nervous and mental disorder have been developing a database of cases treated at these 27 institutions. In that regard, we conducted a survey of inpatients with muscular dystrophy and other neuromuscular disorders based on data collected by the National Hospital Organization and National Center of Neurology and Psychiatry. Herein, we examined data obtained between 1999 and 2010 in order to evaluate the medical condition of inpatients with muscular dystrophy in Japan.

2. Subjects and methods


The database includes numbers of inpatients, gender, age, diagnosis, respiratory condition, nutritional state, number of death cases, causes of death, and other relevant findings from data collected annually on October 1 every year since 1999. We examined these data using longitudinal and horizontal analyses.

3. Sequential changes in total numbers of inpatients treated at muscular dystrophy wards of National Hospital Organization and National Center of Neurology and Psychiatry

The total numbers of inpatients treated at the muscular dystrophy wards of the National Hospital Organization and National Center of Neurology and Psychiatry were quite consistent during the examination period. The lowest number of inpatients was 2066 in 2007 and the highest was 2193 in 2003 (Fig. 1).

3.1 Details regarding number of inpatients

The number of inpatients with Duchenne muscular dystrophy gradually decreased (882~770) every year (Fig. 2), whereas that of those with myotonic dystrophy gradually increased (327~411) (Fig. 3). The numbers of inpatients with other types of muscular dystrophy, such




“Other muscular dystrophies” includes Becker muscular dystrophy, Fukuyama congenital muscular dystrophy, limb-girdle muscular dystrophy, facio-scapulo-humeral muscular dystrophy, Ullrich muscular dystrophy, and others.

“Other neuromuscular disease” includes amyotrophic lateral sclerosis, spinal muscular atrophy, hereditary sensory motor neuropathy, congenital myopathy, and others.

DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy

Fig. 1. Total numbers of inpatients in muscular dystrophy wards of National Hospital Organization and National Center of Neurology and Psychiatry.




The number with Duchenne muscular dystrophy has gradually decreased every year.

TIV, tracheostomy intermittent ventilation; NPPV, non-invasive positive pressure ventilation


Fig. 2. Sequential changes in number of inpatients with Duchenne muscular dystrophy and rate of mechanical ventilation dependence.

as Becker muscular dystrophy (94~105), Fukuyama congenital muscular dystrophy (50~64), limb-girdle type muscular dystrophy (185~216), and facio-scapulo-humeral muscular dystrophy (64~72) showed some fluctuations. Inpatients with spinal muscular atrophy showed a gradual decreasing tendency from 73 in 1999 to 56 in 2010, while those with amyotrophic lateral sclerosis increased every year from 29 to 132 (Fig. 4). Other diseases encountered in these patients included congenital metabolic disease, mitochondrial disease, various types of myopathy, peripheral nerve disease, bone disease, chromosomal abnormalities, spinocerebellar ataxia, neonatal period disease sequelae, infectious diseases, and others, though their numbers were small and equalled around 10% of all diseases.



The number with myotonic dystrophy has gradually increased every year.

Fig. 3. Sequential changes in number of inpatients with myotonic dystrophy and rate of mechanical ventilation dependence.




The number with amyotrophic lateral sclerosis has gradually increased every year.

Fig. 4. Sequential changes in number of inpatients with amyotrophic lateral sclerosis.

3.2 Sequential changes in respiratory care for inpatients and rate of mechanical ventilation dependence

The rate of mechanical ventilation use in 1999 was 37.9%, which gradually increased to 62.9% in 2010 (Fig. 5), while that for Duchenne muscular dystrophy patients in 1999 was 58.7% and gradually increased to 85.1% in 2010 (Fig. 2). Although the total number of inpatients with Duchenne muscular dystrophy gradually decreased, cases of non-invasive ventilation gradually increased and tracheostomy cases were also slightly increased. The rate of mechanical ventilation use for myotonic dystrophy patients in 1999 was 20.3%, which gradually increased to 55.7% in 2010 (Fig. 3).



The rate of mechanical ventilation use in 1999 was 37.9%, which gradually increased to 62.9% in 2010.

Fig. 5. Sequential changes in respiratory care for inpatients and rate of mechanical ventilation dependence.



3.3 Analysis of mean age of inpatients

3.3.1 Changes in age distribution of inpatients in muscular dystrophy wards

The age distribution of inpatients in muscular dystrophy wards in 1999 showed 2 peaks. Those with Duchenne muscular dystrophy largely constituted the younger age peak in the 20s, while those with myotonic dystrophy larger constituted the older age peak in the 50s. These age peaks shifted to a higher range and became slightly flattened in 2009 (Fig. 6).


3.3.2 Sequential changes in mean age of inpatients

The mean age of the inpatients in 1999 was 36.6 years old, which gradually increased to 45.3 years old in 2010. That of Duchenne muscular dystrophy patients in 1999 was 23.6 years old, which gradually increased to 29.4 years old in 2010, while that of myotonic dystrophy patients changed only slightly from 51.4 years old in 1999 to 53.6 years old in 2010 (Fig. 7).



Upper: 1999. Lower: 2009. The age distribution of inpatients in muscular dystrophy wards shifted to a higher range over time.

Fig. 6. Changes in age distribution of inpatients in muscular dystrophy wards.



The mean age of the inpatients was gradually increased. DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy; ALS, amyotrophic lateral sclerosis

Fig. 7. Sequential changes in mean age of inpatients.

Gradual changes in age distribution of inpatients with Duchenne muscular dystrophy was observed. The age peak in 1999 shifted to a higher range and became slightly flattened in 2009 (Fig. 8).





Fig. 8. Changes in age distribution of inpatients with Duchenne muscular dystrophy.

3.4 Sequential changes in numbers of patients receiving oral nutrition and those with Duchenne muscular dystrophy who underwent a percutaneous endoscopic gastrostomy

The proportion of patients with Duchenne muscular dystrophy receiving oral nutrition in 1999 was 95.1%, which gradually decreased to 70.6% in 2010. In contrast, the number who required tube feeding, including a nasal nutrition tube and undergoing a percutaneous endoscopic gastrostomy, gradually increased to 107 in 2010.



PEG, percutaneous endoscopic gastrostomy


Fig. 9. Sequential changes in numbers of Duchenne muscular dystrophy patients and those who underwent an endoscopic gastrostomy patients receiving oral nutrition.

3.5 Death case analysis

The total number of deaths reported from 2000 to 2010 was 1307, which ranged from 95-174 annually in a variable pattern (Fig. 10). The number of Duchenne muscular dystrophy patients who died was 409, while that of myotonic dystrophy patients was 363.


The mean age of death among Duchenne muscular dystrophy patients was 26.7 years old in 2000, which gradually increased to 35.1 years old by 2010. On the other hand, the mean age of death for myotonic dystrophy patients was 59.0 years old in 2000 and 59.1 years old in 2010, which was not significantly different (Fig. 10).

The most frequent cause of death among Duchenne muscular dystrophy patients was heart failure, accounting for 47%. As for myotonic dystrophy patients, the most frequent cause was respiratory disorders, such as respiratory failure and respiratory tract infection, which accounted for 64% (Fig. 11).



DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy

Fig. 10. Sequential numbers of deaths and mean age at death reported to the database.



The most frequent cause of death among Duchenne muscular dystrophy patients was heart failure. In contrast, that of myotonic dystrophy patients was respiratory disorder.


DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy

Fig. 11. Causes of death among Duchenne muscular dystrophy and myotonic dystrophy patients (2000~2010).

3.6 Proportional changes in numbers of inpatients in muscular dystrophy wards of each institution

Twenty-seven hospitals in Japan specialize in treatment of muscular dystrophy patients are not same in terms of types of muscular dystrophy of inpatient, disease severity, and actual care. Fig. 12 shows the proportion of inpatients by each institution. The upper figure, which

shows the proportion in 1999, is arranged according to rate of Duchenne muscular dystrophy inpatients. There were significant differences in regard to the proportion of inpatients among the institutions in 1999, which changed over time. In 2009, the proportion of inpatients with amyotrophic lateral sclerosis was notable.




Upper: 1999. Lower: 2009. A~AZ represent the individual institution. Institute AZ, which had lowest rate of DMD patients among institutions in 1999, has no DMD patient in 2009. DMD, Duchenne muscular dystrophy; MD, myotonic dystrophy; ALS, amyotrophic lateral sclerosis

Fig. 12. Changes in proportions of inpatients in muscular dystrophy wards of each institution

3.7 Sequential changes in respiratory conditions of Duchenne muscular dystrophy patients at each institution (1999~2009).

The total number of Duchenne muscular dystrophy patients treated from 1999 to 2009 was 1427. The changes in motor function of the patients were nearly uniform, whereas the therapeutic respiratory conditions varied among the institutions.

Figure 13 presents the respiratory conditions of the patients for the 11-year period from 1999 to 2009. In the 10s, almost all patients keep voluntary respiratory function. In the 20s, various respiratory patterns are observed, which seem not to be different among the institutions. In more than 30s, there were apparent differences among the institutions. Some institutes have no tracheostomy older patients, which generation is generally supposed not to be compensated by non-invasive positive pressure ventilation and use tracheostomy ventilation.



Each cluster indicates a single institution. The vertical axis indicates the course of a single Duchenne muscular dystrophy patient. The respiratory conditions of older patients differed among the institutions. For example, the left oval indicates a tracheostomy case and the right oval a non-invasive positive pressure ventilation case.

TIV, tracheostomy intermittent ventilation; NPPV, non-invasive positive pressure ventilation

Fig. 13. Sequential changes in respiratory conditions of Duchenne muscular dystrophy patients treated at each institution (1999~2009).

4. Conclusion

Wards for patients with muscular dystrophy were originally established in Japan in 1964 and then gradually expanded throughout the country. As a result, approximate 2500 beds are now provided among 27 institutions. In the early days, many of the patients were boys with Duchenne muscular dystrophy, who received education in schools near the hospital where they received care. However, over time, regular public elementary and junior high schools began to accept disabled children, and such patients were then able to receive an education at schools in their home town. Thus, cases of admission for the purpose of education gradually decreased.

On the other hand, progress in therapeutic strategies for respiratory failure (American Thoracic Society Documents, 2004), heart failure (Ishikawa, 1999; Matsumura, 2010) and other complications associated with muscular dystrophy prolonged the life span of affected individuals (Bushby 2010a, b). Now, most inpatients admitted to a muscular dystrophy ward have a severe general condition and many are assisted by mechanical ventilation (Tatara, 2008). In addition, in terms of nutritional control (American Thoracic Society Documents, 2004; Bushby 2010b), the number of percutaneous endoscopic gastrostomy patients with Duchenne muscular dystrophy has gradually increased.

Thus, the age and disease severity of inpatients have been gradually progressed with this changing environment. And social welfare systems related to muscular dystrophy wards in Japan also have been changing during this research. The social role of wards for inpatients with muscular dystrophy has been changing. The gradual increase of number of inpatients with amyotrophic lateral sclerosis means that the ward for patients with muscular dystrophy is no longer only for patients with muscular dystrophy. Present wards have purpose for care and treatment for severe disabilities, not limited to patients with muscular dystrophy.

There are some reports concerned with prognosis of patients with Duchenne muscular dystrophy from single institution belonging to the National Hospital Organization (Ishikawa, 2011; Matsumura, 2011). Just as these reports, we showed the increasing mean age of death among Duchenne muscular dystrophy patients. Although the most frequent cause of death among Duchenne muscular dystrophy patients was heart failure, the progression for cardioprotection therapy to cardiomyopathy (Ishikawa, 1999; Matsumura, 2010) improved the prognosis.

However, the present findings showed that there are apparent differences in regard to the proportion of inpatients and therapeutic conditions among institutions. Hereafter, these differences will be more remarkable. So far almost same therapy has been offered among the National Hospital Organization and National Center of Neurology and Psychiatry. However, these conditions will not continue and may influence the prognosis of patients with muscular dystrophy in Japan.

Social role of wards for patients with muscular dystrophy at establishment, offering patients with muscular dystrophy opportunities of education and treatment, has changed into offering severe disabilities care and treatment. We should consider how to manage these conditions.

5. Acknowledgments

This study was supported by a Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare of Japan.

We are grateful to Dr. Mitsuru Kawai for the kind advice, as well as the members of the FUKUNAGA (1999-2005) and SHINNO (2006-2011) muscular dystrophy research groups of the National Hospital Organization for the data collection.

Institutions specializing in muscular dystrophy treatment in Japan (Fig.14)




Fig. 14. Institutions specializing in muscular dystrophy treatment in Japan

National Hospital Organization:

- Asahikawa Medical Center, Yakumo Hospital, Aomori National Hospital,
- Akita National Hospital, Nishitaga National Hospital, East Saitama National Hospital,
- Shimoshizu National Hospital, National Hakone Hospital, Niigata National Hospital,
- Iou National Hospital, Nagara Medical Center, Suzuka National Hospital,
- Nara Medical Center, Utano Hospital, Toneyama National Hospital,
- Hyogo-cyuo National Hospital, Hiroshima-Nishi Medical Center, Matsue Medical Center,
- Tokushima National Hospital, Oomuta Hospital, Nagasaki Kawatana Medical Center,
- Kumamoto Saishunso National Hospital, Nishibeppu National Hospital,
- Miyazaki Higashi Hospital, Minami Kyushu National Hospital, Okinawa National Hospital

National Center of Neurology and Psychiatry

6. References

- American Thoracic Society Documents (2004). Respiratory Care of the Patient with Duchenne Muscular Dystrophy. ATS Consensus Statement · *American Journal of Respiratory and Critical Care Medicine*, Vol 170, pp 456–465.
- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, for the DMD care considerations working group (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *The Lancet Neurology*, Vol.9, pp 77-93.
- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, for the DMD care considerations working group (2010b). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *The Lancet Neurology*, Vol.9, pp 177–189.
- Ishikawa Y, Bach JR, Minami R (1999). Cardioprotection for Duchenne’s muscular dystrophy. *American Heart Journal* Vol.137, pp 895–902.
- Ishikawa Y, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S, Minami R (2011). Duchenne muscular dystrophy: Survival by cardio-respiratory interventions. *Neuromuscular Disorders* Vol. 21, pp 47–51.
- Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M (2010) · Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. *Internal Medicine* Vol. 49, pp 1357–1363.
- Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S (2011). A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. *Rinsho-shinkeigaku* Vol. 51, pp743-750.

Tatara K, Shinno S (2008). Management of mechanical ventilation and prognosis in Duchenne muscular dystrophy. *IRYO*, Vol. 62, pp 566-571.

Comparison Between Courses of Home and Inpatients Mechanical Ventilation in Patients with Muscular Dystrophy in Japan

Toshio Saito¹ and Katsunori Tatara²

¹*Division of Neurology, National Hospital Organization Toneyama National Hospital*

²*Division of Pediatrics, National Hospital Organization Tokushima National Hospital
Japan*

1. Introduction

In Japan, 27 hospitals specialize in treatment of muscular dystrophy patients, including inpatient care, of which 26 belong to the National Hospital Organization, and the other is the National Center of Neurology and Psychiatry. Since 1999, Japanese muscular dystrophy research groups investigating nervous and mental disorder have been developing a database of cases treated at these 27 institutions. In that regard, we conducted a survey of inpatients and home-mechanical ventilation patients (HMV patients) with muscular dystrophy and other neuromuscular disorders based on data collected by the National Hospital Organization and National Center of Neurology and Psychiatry.

Herein, we examined data obtained in order to evaluate efficacy of mechanical ventilation therapy for HMV patients and mechanical ventilation-dependent inpatients (MV inpatients) with those wards.

2. Subjects and methods

The database includes numbers of inpatients, gender, age, diagnosis, respiratory condition, nutritional state, number of death cases, causes of death, and other relevant findings from data collected annually on October 1 every year since 1999. Additionally we collected the data of HMV patients from 27 institutes for this study.

By using the database and newly collected HMV data, we analyzed the courses of HMV patients group and those of MV inpatients of wards. We compared data of these two groups. Examination points are mechanical ventilation periods, outcome of these two groups, and caregiver for HMV patients.

2.1 Objective diseases

Objective diseases of this study were muscular dystrophy and spinal muscular atrophy, in particular Duchenne muscular dystrophy and myotonic dystrophy. Amyotrophic lateral sclerosis was not included.

2.2 Patients introduced HMV after 1999

The data which we requested 27 institutes specializing muscular dystrophy care was as follows; the number of patients introduced HMV after 1999, diagnosis of disease, gender, age at being introduced HMV, type of mechanical ventilation, such as non-invasive positive pressure ventilation (NPPV) or tracheostomy intermittent ventilation (TIV), present status, death cause for death case, main caregiver, and so on.

2.3 Patients introduced MV in muscular dystrophy wards after 1999

We selected data of newly MV introduced inpatients after 1999 from the database of the muscular dystrophy wards.

3. Results

3.1 Demographic features of HMV patients group and MV inpatients

3.1.1 HMV patients group

HMV patients group included 434 patients from 14 institutes. Gender was male: 356, female: 78. The number of representative disease were as follows; 262 patients with Duchenne muscular dystrophy, 60 myotonic dystrophy, 17 Becker muscular dystrophy, 16 limb-girdle muscular dystrophy, 14 spinal muscular atrophy, and so on (Table 1-1).

Diagnosis	HMV	Inpatient	Total	Death cases
BMD	17	35	52	10
CMD	12	6	18	2
DMD	262	476	738	96
EDMD	2	0	2	
FCMD	16	43	59	13
FSHD	6	33	39	7
LGMD	16	42	58	12
MD	60	222	282	62
MG	1	0	1	
SMA	13	19	32	6
SPMA	0	11	11	4
UCMD	9	1	10	
Mitochondria disease	0	5	5	1
Distal myopathy	2	3	5	2
Congenital myopathy	8	12	20	
Glycogen storage disease	2	1	3	
Other myopathies	3	1	4	
Other dystrophies	4	5	9	
Unknown	1	0	1	
total	434	915	1349	215

BMD, Becker muscular dystrophy; CMD, congenital muscular dystrophy; DMD, Duchenne muscular dystrophy; EDMD, Emery-Dreifuss muscular dystrophy; FCMD, Fukuyama congenital muscular dystrophy; FSHD, facio-scapulo-humeral muscular dystrophy; LGMD, limb-girdle muscular dystrophy; MD, Myotonic dystrophy; MG, myasthenia gravis; SMA, spinal muscular atrophy; SPMA, spinal progressive muscular atrophy, UCMD, Ullrich congenital muscular dystrophy

Table 1-1. Details of disease (HMV: from 14 institutes)